Skip Navigation

Rizwan Romee, MD

Medical Oncology

Make an Appointment
Watch Video


  • Director, Haploidentical Donor Transplantation Program
  • Physician
  • Associate Professor of Medicine, Harvard Medical School


Clinical Interests

  • Advanced myeloid malignancies
  • Haploidentical transplantation
  • NK cell based cellular therapy

Contact Information

  • Appointments617-632-5138 (new)
    617-632-3470 (follow-up)
  • Office Phone Number617-632-3470
  • Fax617-632-4422


Dr. Romee received his MD from Govt. Medical College Srinagar, India. He completed his postgraduate training and hematology and oncology fellowship at University of Minnesota where he also did his post-doctoral training in Dr. Jeffrey S. Miller’s laboratory. Afterward, he did an advanced bone marrow transplant fellowship at Washington University in Saint Louis where he stayed on as faculty before moving to Dana-Farber Cancer Institute.


Rizwan Romee, MD, director of Dana-Farber’s Haploidentical Donor Transplant Program, discusses immunotherapy treatment options for advanced hematologic malignancies. Dr. Romee’s clinical focus includes advanced myeloid malignancies and NK cell based cellular therapy. Learn more about the Hematologic Oncology at Dana-Farber:

Board Certification:

  • Hematology, 2012
  • Internal Medicine, 2008


  • University of Minnesota, Hematology and Oncology
  • Washington University School of Medicine, Advanced Bone Marrow Transplant


  • University of Minnesota, Internal Medicine

Medical School:

  • Government Medical College Srinagar, India


As a translational physician-scientist, my long-term goals are to translate novel aspects of immunology to improve treatments for patients with advanced malignancies. We described human memory-like NK cells with enhanced anti-tumor activity and in a first in human clinical trial demonstrated safety and promising activity of these cells in advanced AML patients. In clinic we are currently testing these memory-like NK cells in combination with novel immune-modulatory agents in patients with advanced malignancies.

The primary focus of my lab-based research efforts is gene manipulation of the key immune cells including Natural Killer (NK) cells to enhance their anti-tumor function and modulate the tumor microenvironment (TME). We are also developing a novel class of immuno-cytokines aimed at selectively targeting the immuno-suppresive cells like MDSCs and Tregs.

I also lead our haploidentical transplant program and we are developing protocols using haploidentical donor transplantation as a platform to incorporate NK cell-based immunotherapy approaches.


Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions